ProQR Therapeutics N.V. (NASDAQ:PRQR) is scheduled to post its quarterly earnings results before the market opens on Tuesday, August 15th. Analysts expect ProQR Therapeutics N.V. to post earnings of ($0.51) per share for the quarter.

ProQR Therapeutics N.V. (NASDAQ:PRQR) last announced its earnings results on Wednesday, May 17th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.02. On average, analysts expect ProQR Therapeutics N.V. to post $-2.18 EPS for the current fiscal year and $-2.03 EPS for the next fiscal year.

ProQR Therapeutics N.V. (NASDAQ PRQR) opened at 5.20 on Tuesday. The firm’s market capitalization is $124.10 million. The firm has a 50 day moving average price of $5.12 and a 200-day moving average price of $4.75. ProQR Therapeutics N.V. has a 12 month low of $3.65 and a 12 month high of $8.70.

A number of brokerages have recently commented on PRQR. Zacks Investment Research lowered ProQR Therapeutics N.V. from a “hold” rating to a “sell” rating in a report on Wednesday, April 19th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of ProQR Therapeutics N.V. in a report on Tuesday, June 20th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $14.05.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at

ProQR Therapeutics N.V. Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Earnings History for ProQR Therapeutics N.V. (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with's FREE daily email newsletter.